Industry View: Consequences of the New Variations Regulation for the ECTD

Pharma IQ

Electronic submissions can substantially reduce submission time, allowing for a quicker release of products onto the market. However, the implementation and handling of eCTD can be problematic due to different standards at each European agency. In this interview Dr. Hannes Perschinka, Regulatory Support at Gebro Pharma, speaks to Andrea Charles from Pharma IQ, about how new Variations Regulation has impacted eCTD and the key challenges for eCTD lifecycle management.  Per...
To continue reading this story get free access